These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 29229605)

  • 61. MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.
    Koetz-Ploch L; Hanniford D; Dolgalev I; Sokolova E; Zhong J; Díaz-Martínez M; Bernstein E; Darvishian F; Flaherty KT; Chapman PB; Tawbi H; Hernando E
    Pigment Cell Melanoma Res; 2017 May; 30(3):328-338. PubMed ID: 28140520
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 63. LncRNA SAMMSON Mediates Adaptive Resistance to RAF Inhibition in BRAF-Mutant Melanoma Cells.
    Han S; Yan Y; Ren Y; Hu Y; Wang Y; Chen L; Zhi Z; Zheng Y; Shao Y; Liu J
    Cancer Res; 2021 Jun; 81(11):2918-2929. PubMed ID: 34087780
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sorafenib induces synergistic effect on inhibition of vemurafenib resistant melanoma growth.
    Srivastava A; Moorthy A
    Front Biosci (Schol Ed); 2019 Mar; 11(1):193-202. PubMed ID: 30844744
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway.
    Jiang S; Jiang T; Huang H; Chen X; Li L; Wang Z; Fei J; Liu C; Liu Z; Cheng Y
    Chem Biol Interact; 2022 Jan; 351():109747. PubMed ID: 34813779
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
    Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T
    Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
    Tate SC; Burke TF; Hartman D; Kulanthaivel P; Beckmann RP; Cronier DM
    Br J Cancer; 2016 Mar; 114(6):669-79. PubMed ID: 26978007
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAF
    Kim T; Havighurst T; Kim K; Albertini M; Xu YG; Spiegelman VS
    Mol Carcinog; 2018 May; 57(5):678-683. PubMed ID: 29369405
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma.
    Zhao B; Cheng X; Zhou X
    Melanoma Res; 2018 Dec; 28(6):521-526. PubMed ID: 30192303
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Everolimus selectively targets vemurafenib resistant BRAF
    Ruzzolini J; Peppicelli S; Andreucci E; Bianchini F; Margheri F; Laurenzana A; Fibbi G; Pimpinelli N; Calorini L
    Cancer Lett; 2017 Nov; 408():43-54. PubMed ID: 28826720
    [TBL] [Abstract][Full Text] [Related]  

  • 74. miR-579-3p controls melanoma progression and resistance to target therapy.
    Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G
    Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Rescue of cell cycle progression in BRAF
    Toress-Collado AX; Nazarian R; Jazirehi AR
    Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.
    Dratkiewicz E; Simiczyjew A; Pietraszek-Gremplewicz K; Mazurkiewicz J; Nowak D
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877948
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Quantitative Proteomics Links the Intermediate Filament Nestin to Resistance to Targeted BRAF Inhibition in Melanoma Cells.
    Schmitt M; Sinnberg T; Nalpas NC; Maass A; Schittek B; Macek B
    Mol Cell Proteomics; 2019 Jun; 18(6):1096-1109. PubMed ID: 30890564
    [TBL] [Abstract][Full Text] [Related]  

  • 78. EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.
    Laurenzana A; Margheri F; Biagioni A; Chillà A; Pimpinelli N; Ruzzolini J; Peppicelli S; Andreucci E; Calorini L; Serratì S; Del Rosso M; Fibbi G
    EBioMedicine; 2019 Jan; 39():194-206. PubMed ID: 30611716
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
    Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.